Zuellig Pharma
Concise Prescribing Info
Reduction of elevated IOP in patients w/ open-angle glaucoma, chronic angle closure glaucoma, ocular HTN. Reduction of elevated IOP in paed patients w/ elevated IOP & paed glaucoma.
Dosage/Direction for Use
Adult (including the elderly), paed patients 1 drop in the affected eye(s) once daily. Should not exceed once daily. 
Special Precautions
May gradually increase iris pigmentation, change eyelashes & vellus hair in the treated eye; eyelid skin darkening. Potential for heterochromia in patients receiving unilateral treatment. Aphakic & pseudophakic patients w/ torn posterior lens cap, or in patients w/ known risk factor for macular edema. Inflammatory neovascular glaucoma; history of herpetic keratitis. Avoid in patients w/ active herpes simplex keratitis & w/ a history of recurrent herpetic keratitis specifically associated w/ prostaglandin analogues. Remove contact lenses before installation due to benzalkonium Cl content. Do not drive or use machines until transient blurring of vision is resolved. Pregnancy & lactation. Childn <1 yr. Pre-term infants (<36 wk gestational age).
Adverse Reactions
Eye irritation (burning, grittiness, itching, stinging & foreign body sensation), eye pain, eyelash & eyelid vellus hair changes (increased length, thickness, pigmentation & number of eyelashes), ocular hyperaemia, iris hyperpigmentation, blepharitis, conjunctivitis. Macular oedema. Herpetic keratitis. Nasopharyngitis & pyrexia.
Drug Interactions
Paradoxical elevations in IOP w/ other prostaglandins, prostaglandin analogs or prostaglandin derivatives.
MIMS Class
Antiglaucoma Preparations
ATC Classification
S01EE01 - latanoprost ; Belongs to the class of prostaglandin analogues. Used in the treatment of glaucoma.
Xalatan ophth soln 50 mcg/mL
2.5 mL x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in